Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 3/20 | 0.39 |
| ▸ | YAP1 | P46937 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19667656 | 0.85 | ESR2 (0.42) | ESR2P2RX3TLR9TLR7GCK | |
| SCHEMBL30207824 | 0.85 | ESR2 (0.42) | ESR2P2RX3TLR9TLR7GCK | |
| SCHEMBL19667142 | 0.83 | ESR2 (0.48) | ESR2P2RX3TLR9TLR7TMEM97 | |
| SCHEMBL30207857 | 0.83 | ESR2 (0.48) | ESR2P2RX3TLR9TLR7TMEM97 | |
| SCHEMBL30207999 | 0.82 | ESR2 (0.47) | ESR2GPR119NR1H2 | |
| SCHEMBL19667429 | 0.82 | ESR2 (0.47) | ESR2GPR119NR1H2 | |
| SCHEMBL19667401 | 0.81 | ESR2 (0.42) | ESR2P2RX3TLR9TLR7GCK | |
| SCHEMBL30207971 | 0.81 | ESR2 (0.42) | ESR2P2RX3TLR9TLR7GCK | |
| SCHEMBL23684726 | 0.81 | PTGDR2 (0.52) | ESR2TLR9TLR7TMEM97SIGMAR1 | |
| SCHEMBL19667442 | 0.81 | P2RX3 (0.42) | ESR2P2RX3TLR9TLR7GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | ESR2 2951/4885P2RX3 3952/4885TLR9 3850/4885 |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | ESR2 2951/4885P2RX3 3952/4885TLR9 3850/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | ESR2 2951/4885P2RX3 3952/4885TLR9 3850/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | ESR2 2951/4885P2RX3 3952/4885TLR9 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.